2 November 2021 - Telix is delighted to announce that the TGA has approved Illuccix (kit for the preparation of 68Ga PSMA-11 injection) for the diagnostic imaging of men with prostate cancer. 

The TGA has granted Illuccix a broad clinical indication comprising:

• Patients with prostate cancer who are at risk of metastasis and who are suitable for initial definitive therapy
• Patients with prostate cancer who have suspected recurrence based on elevated serum prostate specific antigen level

Read Telix Pharmaceuticals press release